Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Conference · 2026-11-17
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Thanks so much for joining us at Jeffrey's London Healthcare Conference. My name is Albert Zhang, associate on our Akash Talar team here at Jeffrey's. I work closely with Manoj, who covers Liquidea and has done some really great work here. I'm pleased to welcome Michael Cassetta, chief operating officer, chief financial officer from Liquidea, and Jason Adair, chief business officer. Before we jump into questions, I'll turn it over to Michael and Jason for opening remarks.
Yeah, thanks Albert for having us. Thanks, really appreciate being here at Jefferies. Just first, Roger does send his regards. He did get hung up in some of the travel disruption this weekend and was unable to make it, but Jason and I will try to hold the fort down here. First, I think what's most important for us is patients are at the center of everything we do as a company at Liquidea. And this is why the settlement that we entered into in October was so important. You know, it gives certainty to existing PHILD patients who benefit so greatly from our drug. It also gives certainty to the PH community as a whole. We are- For where we are right now, we couldn't be more excited for the path forward. All we've done since June of 2025, when we launched Utropia, was execute. We've been able to achieve over a 30% market share by the end of September in an entrenched market where the market leader had a 20-year head start. We have the best. Sales team, the best commercial team, the best market access team, and we have a, you know, first class patient support services program. And, you know, as we move forward through the rest of 26 and into 27, we couldn't be more excited for what's to come. We feel, you know, extremely lucky to be able to service these patients as we move forward, especially, you know, these PAH patients, and look forward to a great year in 2027 and beyond.
Great. Thanks so much. Maybe we can start off with a bigger picture question. With litigation overhand not removed, I think investors can now shift their attention to the underlying business and the pipeline. As you look through 2027 and maybe even further off to 28, 29, what would you highlight as the two or three most important milestones for the liquidity story? And perhaps more specifically, what do you think the investors are still underappreciating about Liquidea's growth opportunity here?
Yeah, it's a great question. You know, as we look, you know, really the world changed the day we signed that settlement in mid-October. I think what's most important for the rest of 2026 is to show that we can still be a growth story. And, you know, we feel that we're in a really good position at earnings last week. We talked about where we were for the month of October, and what I would say, and I don't think this is controversial, we believe October of 2026 is going to be the most disruptive month of our launch. If you look at our referral rate in October of 2026, it was 75% of where we were in Q3 on a daily rate. We're very happy with that. We're very encouraged with what we've seen in October. We're very encouraged with what we've seen for the first half of November. And we believe that we're going to grow from this base as we move forward. And that is extremely important for how we see the PAH market for Eutrepia moving through the rest of 26 and into 27 and 28. But like Roger said, we are a show me story. We're planning to do that. We're planning to do that while also achieving over 50% operating margins in 2027. So our SG&A expenses as a percentage of sales will come down quarter on quarter. We will grow our R&D costs quarter on quarter as we move forward. And this time next year, our plan is to have 10 clinical trials in place, three of which will be registrational studies with L606 in PHCOPD, in PHILD, And, you know, and hopefully also be in a pivotal phase three study in systemic sclerosis with Raynaud's phenomenon. So it is an exciting time for Liquidea, and I think for us, it's all about execution now. As you said, the legal overhang is gone. We can focus solely on the task at hand here, and we feel that, you know, it is a great time at Liquidea, and we're going to create a tremendous amount of value for shareholders. And most importantly, we're going to provide a tremendous amount of benefit for patients.
Got it. Understood. I want to first touch on Utripia and its commercial opportunity. You've talked about roughly 25K treated PAH patients are now already receiving aprostocycline, and importantly, you've positioned Utripia as an option not just for patients in health therapies, but also potentially for patients on oral and parenteral as well. If we think about those three existing treatment pools, oral, inhaled, and parenteral, which do you think see as the most actionable switching opportunity over the next 12 or 24 months?
Yeah, what I think is most exciting about Eutrepia is obviously our product profile and the flexibility that we provide. Our ability to titrate to higher doses, we believe, than any other inhaled prostacyclin. We're also the only inhaled prostacycline in our label having a dosing regimen of between three and five times per day. You know, we look at the entire opportunity. If you look at the prostacycline market in PAH, it's roughly $4 billion in total based on our estimates. We believe we have access to the vast majority of that $4 billion. This is why, as part of those 10 trials that I talked about, we're going to do a lot of phase four open label studies in oral transitions. We're going to do an oral, a study showing eutropia, using it only three times a day. We're going to do a study of perennial transitions on background wind repair therapy. So we're excited. We think that this opportunity in PAH is a massive opportunity for us. It is our primary focus as we move forward. As I said, we have a sales force that is laser focused with tremendous relationships. And again, we feel very confident that we're going to be able to continue to deliver and continue to deliver sequential growth as we move forward through the rest of 2026 and through 2027.
I just want to follow up a quick one on the Aura side. You have an ongoing study looking at transitions from SELEXPAC, I believe, and how important is establishing a standardized transition protocol to unlock that population there?
Sure, I can take that. So a lot of what we're doing with Phase 4 is to create data that will be ours that we can publish, but it's really reflecting what's already happening in the real world. So to the point that since launch, we've seen transitions, and we've seen patients go from an oral prostacycline to inhaled. And one of the main reasons for that has to do with tolerability. So we think of inhaled as local delivery for local disease. The oral products, you literally have to gut through them as they activate, you know, receptors in the intestines. So let's avoid all of that. And so we have entered a single-site study where we're going to look to move patients from oral CelexaPeg to doses of Eutropia and see if we can take them higher. The ultimate goal is to see if we can make those patients better or get more utility out of it. But the primary goal for that study is really safety, that we're transitioning those patients in a safe way, not putting them at risk, and then see if we can make them better. Our hope is that that data then will also start to inform maybe an algorithm that we could use in our medical information to explain to other physicians how they could safely titrate patients.
Excellent. Just maybe continue on the commercial side. Another important question following the settlement is obviously, you know, how are we thinking about existing PHILD patients on eutropia? You've been clear that patients are already receiving eutropia for PHILD are not required to switch, and so far you're not seeing formulary changes or indications Patients that payers are prerogatively trying to move patients into alternative therapies. As we move into 27 and annual reauthorization begins, how should we think about the actual risk to existing PHLD patients?
Yeah, so when we think about existing patients, one of the things we talked about at earnings last week was that we shift to more patients in October of 26 than in any other month during the launch. So we have a great patient base that is growing. As you said, what happens in the reauthorization process in early 27, you know, the reauthorization process is very simple. It's a communication between payers and doctors, and the two main questions that are asked are, is the patient still on the therapy, and is the patient still benefiting from that therapy? Nothing that has happened in the last 60 days impacts that. We have contracted broadly across both Part D and commercial. We do not see any changes and therefore our belief is that if a doctor wants to keep an existing PHILD patient on utopia, they will be able to do that. And like I said, we will continue to service all of our patients on utopia to make sure they're getting the best service and the best care that they can.
Got it, that's definitely some of the concerns before the earnings call, but you've already addressed that. Maybe shifting to clinical programs supporting utopia's differentiated profile. You are planning to initiate EZPH in 2027. I think this one is particularly interesting because real world evidence could help demonstrate how physicians are actually taking advantage of utopia's flexibility The ability around dosing, frequency, and titration, and which clinical and utilization endpoints do you think will be most important in that registry, and how do you plan to follow patients, and perhaps more importantly, how do you envision translating that real-world evidence into something commercially differentiated?
Well, it's a fair question. Registry studies are very valuable in multiple diseases, including in PAH, and I think you kind of answered the question in your question, which is, what is happening in the real world? And given the flexibility that Mike mentioned related to dose frequency, the range of dose, as well as the speed of titration, we want to collect as much as we can over as long a period as we can. So the ultimate value will be informing future publications that we share with the medical community on how that is being used in the real world. I mean, we're going to do other studies also that are controlled studies, but the registry study is exciting to get kicked off next year.
Understood. Maybe move beyond PAH. I want to spend some time on the RE-WARM study and the opportunity in systemic sclerosis associated with Reynolds phenomenon. You're now initiated the phase two dose finding study and received fast track designation with the study parameter completion expected in Q1-27, I believe. I guess my question is, what magnitude of improvement in symptomatic attacks or attack-free days would give you confidence to move into phase three? And maybe number two, how will the phase two findings inform both dose selection and primary endpoint for the pivotal study?
Yeah, so great question. There's a lot of detail there. I think first and foremost is making sure that people understand that this is a disease with no treatment. So a scleroderma or systemic sclerosis is a rare disease. 90 to 95 percent of these patients have Raynaud's attacks. So what we're going to focus on to look for the signal is those patients who have moderate to severe Raynaud's, so they have a very high attack rate, and we're running the study in the winter season. So we're trying to figure out, first, is there a dose that gives us the systemic exposure that we would want to see that improves the vasodilation in the fingers? And we're going to measure many things, including what is the impact on attack rate. There's two arms to that study. One is a fixed-dose arm, and one is a titratable arm. So we don't actually know yet what is the dose going to be. But once we figure out one or maybe more than one dose, if we're successful, we'll move that right into a pivotal study next winter. So this is an indication where we don't want to get ahead of our skis. We want to make sure that we have a viable dose. And then if we do, we can talk a lot more about the opportunity and what that Phase III study looks like. But I can give you confidence that we're working in the United States with the experts, and there's a lot of excitement. Because the reason to believe is already out there in the medical literature. We know that infused prostacycline analogs like Isloprost are used in Europe to treat Raynaud's. We know that other companies have studied different formulations of triprostanol, an oral formulation to try to treat Raynaud's. But really it's the balance of exposure and tolerability. And that kind of speaks to the advantages of eutropia that we see in PAH, and we hope to see in scleroderma with Raynaud's as well.
Understood. That's super helpful. And maybe let's now move to L606. I know a lot of investors are interested in that. On the clinical development side, you are expecting to initiate Amplify PAH in 27. Can you walk us through how you are thinking about the pivotal trial design and in particular what kind of PAH patient population are you targeting in terms of baseline risk and background therapy? And what magnitude of clinical benefit would establish a truly differentiated role for L606 versus utopia, and maybe other in-health problems to psycholimus.
So, we should put it into context of why we're doing that study. We, up until the settlement, we had a path forward, which was a 505B2 path, where we had an agreement with the FDA that a single well-controlled trial would allow us two indications. That's RESPIRE. We're doing that global study now, and PHILD. But once it became clear that we would not be able to reference Tyveso in a future filing, We wanted to make sure that we had a second study that would give us the PAH indication. We were already preparing for that study ahead of the settlement because we wanted to have data that would make us commercially relevant in the future when we were selling that product. Now that study is going to be a very important part to our registration strategy. So with that program, with the PHILD study, we'll go with B1. We'll need a second study that gives us the PAH indication. There will be other data that we need to support, to create, to support the approval. As for the endpoints in the Amplify PAH study, I would save that to when we list it in ClinTrials. We all know that inhaled troposinol works, and we know that L606 works in PAH patients because we've been running a multi-year open-label study in the United States in both PAH patients and PHILD patients. So we have a high degree of confidence. As for the endpoints, we can talk about that at a future meeting.
And Albert, just to add, I mean, our goal and belief and plan is to have enrollment complete in 28, have data in 29, and be able to file the NDA thereafter. So we're excited for what's to come in L606.
That's totally fair, and maybe build on top of that, when we discussed L606 last year, one of the key points were the potential benefits of sustained triposinal exposure. And including consistent peak to trough effect combined with the twice daily administration. Now that we are seeing Utripia has commercial success, I think one of the more important question now is how do you ultimately position the two products together? And how do you envision the segmenting between Eutropia and L606 within the PAH market over the longer term, and if L606 delivers the profile you are targeting, could it eventually replace a meaningful portion of Eutropia?
Yeah, so I think what we have to understand is, you know, I think the goal is we move forward, and if you segmented from existing patients that will be on Eutrepea at the time that we launch L606 versus new patients, I think our belief, if we're as successful as we believe we're going to be with L606, you know, we're not saying all patients, but we would believe the majority of patients would look to start on L606 for the benefits that we've already talked about. Existing patients, again, these are very sick patients, and doctors, we believe ultimately a transition from Eutropia to L606 is, in some instances, will happen, but it's going to be on a case-by-case basis. Right now, we have the best-in-class DPI in inhaled prostacyclins. We believe we will have the best nebulized form in And ultimately, to be able to have that product offering we think is going to be beneficial for doctors, for patients. And ultimately, as we look forward into the far future, I think L606 will be the dominant force. Eutropia with systemic sclerosis with Raynaud's, if successful, will focus there. And then also, we do believe that there will be patients that will prefer Eutropia. But being able to give that option, you know, patients have not had option in a long time, they finally do, to be able to give more options as we move forward through our innovation, where, you know, we think that'll be a big benefit to the space.
Assuming the trial delivers, and the next question, obviously, is the regulatory pathway. You've indicated that the pathway for L606 is 505B1, which is different from Eutropia. What FDA interactions or feedback give you the confidence that the current clinical development package will be sufficient to support that following, and as you evaluate the path into that 2029, where do you see the greatest remaining regulatory or operational risk?
Well, so what I would say is that we had very clear alignment on the B2 path with the agency before. We changed the overall pharmacodynamics by going to twice daily. So we weren't needing to reprove that triprostanol is a safe and effective molecule. We just needed to demonstrate that twice daily doesn't lose any potential efficacy, and we're very confident on that based on what we've seen in the U.S. So with that knowledge that a large, well-controlled trial will give us a PHLD indication, you know, it's, you know, from a... A regulatory strategy, just now having a second trial that's a PAH trial, is just to complement that, since we can't rely on the B2 anymore. So I feel like that we have a very clear plan on how we can get both trials to read out in 29, and there will be some supplemental studies that we would need to do that you would not need to do under a B2 path. But these are things that are easily achievable within that critical path timeline.
Understood. And maybe just another one, 606, which is related to the regulatory discussion perhaps as important as the IP issue, right? Mm-hm. Recent earnings call, you've said that the claims of the 327 patent are structured. I think it was per breath triposinal delivery, whereas L606 nebulizer delivers the entire loading dose rather than, you know, a fixed. How should investors think about the broader freedom to operate landscape for L606, and are there any other patents, claims or potential litigation risks that will need to be addressed before commercialization?
So we have a clear path to market with L606. You kind of touched on the 327 patent, right? 327 patent was a method of use patent, really designed around how Tyveso delivers inhaled triprostanol. And that Tyveso device is distinctly different than the device that we're using in L606. So that product is dosed by breath. You have to take more breath to get to higher doses. In our case, our nebulizer, which is a next-generation breath-actuated device, The whole dose is loaded into the device, and the patient's in control of how they inhale that product. So I would say that we have a very clear line of sight to getting our product to market. As for future litigation, you know, I can tell you that we're ready. We're very seasoned, and I think that we've been pretty successful along the way with different patents. Clearly, we were disappointed with the outcome here, but we decided for patients, right? We wanted to keep our drug in the market. I think we've done a good job showing that we're always going to keep patience in mind, and the future is very exciting as we think about getting back to the referral rate that we saw in the third quarter.
Understood. That's really helpful. And maybe beyond PH, PH-IOD and PH-COPD, which pulmonary hypertension or fibrotic lung disease indications are the highest priority for L606?
You know, so the great news is there's so many things that we could pursue, right? And the fact that we get asked this question makes it very exciting. You know, the news on our last earnings call was PHDOPD. We're going to prioritize L606 there, and I think why is that important? It's a very large disease. You know, it's at least 300,000 patients. There's no approved therapy. There's been a lot of learning along the way in terms of how do you design a trial to be successful. But more importantly, with L606 and the twice-daily formulation, we think that we can achieve very high levels with a better tolerability profile and that more uniform exposure should translate into, we hope, improved efficacy for PHCOPD patients. Outside of that, you touched on fibrosis. We get that question a lot with IPF and PPF because of the Teton studies that United is running. And I think what we would point out there is that those studies have been successful in their design, but they've been limited in their dosing. So Tyveso was dosed at 9 to 12 breaths a session four times a day. What we've already shown with Eutrepia is that we can achieve levels that are two and three times that. We ran a previous study called ASCENT, which was in PH-ILD patients, and we looked at titrating patients to high levels very quickly. So our next idea in IPF and PPF would be to repeat a study that is similar to that. Can we test the hypothesis that exposure drives efficacy in a non-PH indication? So we haven't rolled out the details of that yet, but that would be our next step, Because if we're successful in showing that we can dose higher and potentially get improved efficacy, then we can bake that into whatever the next pivotal study will be.
Understood. I know we are close on time. I want to squeeze one more question in. Maybe regarding capital allocation. You've ended the third quarter with around $400 million cash and you've outlined roughly around $380 million off net settlement payments through 2027. As you look beyond those settlement payments and assuming Utripia continues generating meaningful cash flow, how are you thinking about the balance between investing in your internal pipeline and maybe pursuing external opportunities there?
Yeah, it's a great question. You know, as we look at capital, you know, as you mentioned, as part of the settlement, we had to make certain payments to, you know, to United Therapeutics. I think the good news is there's no ongoing, after we make the final payment in April of 2027, there is no ongoing royalty. There are no further payments. Any cash that we earn will be, you know, for Liquidea and its shareholders, which is very important. Also, as I said earlier, you know, we are... You know, we believe that we will show continued growth of Eutrepia through Q4 and, you know, all the way through 27 and beyond. You know, we're going to be able to do that at 50% operating margins. So our plan and our goal is to generate a significant amount of positive cash and free cash flow in 2027. Now, with that in mind, we have, you know, our docket is very full from a clinical point of view. As we said, we have 10 trials, three of which are going to be registrational trials. With that being said, we are always evaluating what's out there, what new innovation is out there. As Jason said and as I said earlier, the center of everything we do is for patient benefit. And if we feel there's an opportunity, whether it's a clinical opportunity or a commercial opportunity, because I believe we've shown an ability to launch and commercialize a product, I think we'd be good partners for a lot of different companies, and we'll continue to evaluate that. And if we think it's in the best interest of shareholders and create additional value, We won't hesitate to do that, but I think our priorities are very clear in the short term, but we're always going to keep our eye on the long term as well.
Excellent. I think we might run over a little bit, but Mike, Michael, Jason, thank you so much for joining us and for the discussion, and thanks, everyone, for joining. Thanks, Albert.
0:00 to 26:00 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Thanks so much for joining us at Jeffrey's London Healthcare Conference. My name is Albert Zhang, associate on our Akash Talar team here at Jeffrey's. I work closely with Manoj, who covers Liquidea and has done some really great work here. I'm pleased to welcome Michael Cassetta, chief operating officer, chief…
Michael Kaseta: Yeah, thanks Albert for having us. Thanks, really appreciate being here at Jefferies. Just first, Roger does send his regards. He did get hung up in some of the travel disruption this weekend and was unable to make it, but Jason and I will try to hold the fort…
Also speaking: Jason Adair